|
|
|
| The 3rd Process Development for Cell Therapies Summit is your paramount gathering dedicated to advancing process robustness, scalability, speed, and affordability. Driving Process Robustness, Scalability, Speed & Affordability, ensuring the rapid advancement of highly efficacious products through clinical trials, securing a market-ready status with competitive commercial viability. Find out more here. |
|
|
|
|
Hello Cell & Gene readers, I'm happy to bring you March's most-clicked articles. Enjoy! Erin Harris, editor in chief
Follow me on X |
|
|
MARCH'S BEST FEATURED EDITORIAL |
|
|
|
The Future Of mRNA For Cancer Treatment | By Life Science Connect Editorial Staff | As additional mRNA-based cancer immunotherapies vaccines enter clinical development, operational and supply chain challenges must be addressed to reduce turnaround times and COGS. |
|
|
|
MARCH'S BEST INDUSTRY INSIGHTS |
|
|
FDA Steps Up Support For Advanced Manufacturing Technologies | By Bikash Chatterjee, Pharmatech Associates | Examine the potential of the FDA and NIST's MOU to provide critical technical guidance that could greatly standardize the approaches to implementing AMTs, such as those used in continuous manufacturing. |
|
|
7 Steps For Allogeneic Cell Therapy Success | By John Lee, Patricia Lindler, David Aponte Jr., and Tatiana Nanda, The Center for Breakthrough Medicines | To prepare allogeneic, or "donor-derived," CAR T cells for commercial scale, you must consider scale-up, aseptic processing, single-use systems, facility design, starting material, supply chain, and logistics. |
|
|
|
|
|
|
|
| Connect With Cell & Gene: |
|
|
|
